Department of Surgery, West Virginia University School of Medicine, Morgantown, West Virginia.
Department of Surgery, West Virginia University School of Medicine, Morgantown, West Virginia; Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Morgantown, West Virginia.
Surg Obes Relat Dis. 2023 Aug;19(8):832-840. doi: 10.1016/j.soard.2023.01.021. Epub 2023 Feb 15.
Few studies have examined the adjuvant use of antiobesity medications with surgery, especially in the pre- and early postoperative periods.
Evaluate the impact of adjuvant pharmacotherapy on bariatric surgery outcomes.
University hospital, United States.
A retrospective chart review of patients receiving adjuvant pharmacotherapy for obesity treatment and bariatric surgery. Patients received pharmacotherapy either preoperatively if their body mass index was >60, or in the first or second postoperative years for suboptimal weight loss. Outcome measures included percentage of total body weight loss as well as comparison with the expected weight loss curve as determined by the Metabolic and Bariatric Surgery Risk/Benefit Calculator.
A total of 98 patients were included in the study, with 93 (94.9%) undergoing sleeve gastrectomy and 5 (5.1%) undergoing Roux-en-Y gastric bypass surgery. During the study period, patients were prescribed phentermine and/or topiramate. At postoperative year 1, patients who received pharmacotherapy preoperatively lost 31.3% of their total body weight (TBW) compared with 25.3% TBW for patients with suboptimal weight loss who received medication in the first postoperative year, and 20.8% TBW for patients who did not receive any antiobesity medication in the first postoperative year. Using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) curve for comparison, patients receiving medication preoperatively weighed 2.4% less than expected, whereas patients receiving medication during the first postoperative year weighed 4.8% higher than expected.
For patients having bariatric surgery who fall below the expected MBSAQIP weight loss curve, early initiation of antiobesity medications can improve the weight loss, with preoperative pharmacotherapy having the greatest effect.
鲜有研究探讨肥胖症治疗药物与手术联合应用的辅助作用,尤其是在术前和术后早期阶段。
评估辅助药物治疗对减重手术效果的影响。
美国大学医院。
回顾性分析接受肥胖症治疗辅助药物治疗并接受减重手术的患者病历。如果患者的体重指数(BMI)>60,则在术前接受药物治疗;或在术后 1 年或 2 年内接受药物治疗,以实现不理想的体重减轻。主要转归指标包括体重总减轻百分比,以及与代谢和减重手术风险/获益计算器(Metabolic and Bariatric Surgery Risk/Benefit Calculator)确定的预期体重减轻曲线的比较。
共有 98 例患者纳入研究,其中 93 例(94.9%)接受袖状胃切除术,5 例(5.1%)接受 Roux-en-Y 胃旁路手术。在研究期间,患者接受了 phentermine 和/或托吡酯治疗。术后 1 年,接受术前药物治疗的患者体重减轻了 31.3%,而接受术后第 1 年药物治疗的体重减轻不理想的患者体重减轻了 25.3%,未接受任何术后第 1 年抗肥胖药物治疗的患者体重减轻了 20.8%。与代谢和减重手术认证和质量改进计划(MBSAQIP)曲线进行比较,接受术前药物治疗的患者体重比预期减轻了 2.4%,而接受术后第 1 年药物治疗的患者体重比预期增加了 4.8%。
对于接受减重手术且体重减轻低于 MBSAQIP 预期曲线的患者,早期开始使用抗肥胖药物可以改善体重减轻,术前药物治疗效果最佳。